MetaCap

GridAI Technologies (GRDX) vs Serina Therapeutics (SER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GridAI Technologies (GRDX) has outperformed Serina Therapeutics (SER) over the past year, gaining 20.6% versus a loss of 71.9%. Over five years, SER leads with a -95.6% price change compared with -100.0% for GRDX. GridAI Technologies is the larger company by market cap ($32.4 million vs $29.8 million), about 1.1 times the size.

Serina Therapeutics converts more of its revenue into profit, with a net margin of -14755.4% versus -17634.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRDX+20.61%SER-71.93%
+171%+44%-84%
Nov 21, 20251 yearNov 20, 2026
GRDX-99.99%SER-96.03%
+46%-30%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRDX versus SER key metrics
MetricGRDXSER
Share price$3.16$1.12
Market cap$32.44M$29.76M
1-day change-8.41%-6.67%
YTD return-32.19%-41.45%
1-year return+20.61%-71.93%
5-year return-99.99%-95.64%
EPS (TTM)$-5.65$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$36.25K$130.00K
Revenue growth (YoY)—+132.14%
Net income (latest FY)$-6.39M$-19.18M
Gross margin-1813.56%—
Operating margin-19539.98%-18478.46%
Net margin-17634.42%-14755.38%
52-week high$6.93$4.26
52-week low$1.87$1.06
Distance from 52-week high-54.39%-73.71%
Analyst consensus—none
Avg. price target upside—+748.21%
Average volume120.78K68.98K
Shares outstanding10.27M26.57M
Employees—16
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRDX has outperformed SER by 92.5 percentage points over the past year.
  • Serina Therapeutics is more profitable, keeping -14755.4 cents of every revenue dollar as net income versus -17634.4 cents for GridAI Technologies.

About GridAI Technologies

GRDX stock →

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.

Health Care · Biotechnology: Pharmaceutical Preparations

About Serina Therapeutics

SER stock →

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

GRDX vs SER FAQ

Which is bigger, GridAI Technologies or Serina Therapeutics?

GridAI Technologies (GRDX) is larger, with a market capitalization of $32.44M compared with $29.76M for Serina Therapeutics (SER).

Which stock has performed better over the past year, GRDX or SER?

GRDX returned +20.61% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.

Are GridAI Technologies and Serina Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons